⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21487190 | 0.82 | — | — | |
| SCHEMBL21488571 | 0.82 | — | — | |
| SCHEMBL28521 | 0.78 | — | — | |
| SCHEMBL330407 | 0.78 | — | — | |
| SCHEMBL80383 | 0.78 | — | — | |
| SCHEMBL27314865 | 0.78 | — | — | |
| SCHEMBL1301286 | 0.78 | — | — | |
| SCHEMBL24869 | 0.78 | — | — | |
| SCHEMBL25433 | 0.78 | — | — | |
| SCHEMBL14817654 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110831926-B | Tetrahydronaphtyl urea derivatives | 持田制药株式会社 | 2023-11-21 | — | — | CN | disclosed |
| EP-3983384-B1 | N-(PHENYL)-INDOLE-3-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GPR17 MODULATORS FOR TREATING CNS DISORDERS SUCH AS MULTIPLE SCLEROSIS | UCB PHARMA GMBH (DE) | 2023-10-11 | — | — | EP | disclosed |
| EP-3983384-A1 | N-(PHENYL)-INDOLE-3-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GPR17 MODULATORS FOR TREATING CNS DISORDERS SUCH AS MULTIPLE SCLEROSIS | UCB Pharma GmbH (DE) | 2022-04-20 | — | — | EP | disclosed |
| US-10927079-B2 | Intermediate compound of novel tetrahydronaphthyl urea derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2021-02-23 | — | — | US | disclosed |
| WO-2020254289-A1 | N-(PHENYL)-INDOLE-3-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GPR17 MODULATORS FOR TREATING CNS DISORDERS SUCH AS MULTIPLE SCLEROSIS | UCB PHARMA GMBH (DE) | 2020-12-24 | — | — | WO | disclosed |
| US-20200239419-A1 | NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2020-07-30 | — | — | US | disclosed |
| US-10669239-B2 | Tetrahydronaphthyl urea derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2020-06-02 | — | — | US | disclosed |
| EP-3617195-A1 | NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVES | Mochida Pharmaceutical Co., Ltd. (JP) | 2020-03-04 | — | — | EP | disclosed |
| CN-110831926-A | Novel tetralinyl urea derivatives | 持田制药株式会社 | 2020-02-21 | — | — | CN | disclosed |
| US-20190337897-A1 | NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2019-11-07 | — | — | US | disclosed |
| US-10399945-B2 | Tetrahydronaphthyl urea derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2019-09-03 | — | — | US | disclosed |
| US-20190023657-A1 | NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2019-01-24 | — | — | US | disclosed |
| EP-1284267-B1 | TRIAZOLE COMPOUNDS HAVING AMIDE LINKAGE | SANKYO CO (JP) | 2004-12-15 | — | — | EP | disclosed |
| US-6653330-B2 | Such as 4'-chloro-4-(5-(3-(2,4-difluorophenyl)-3-hydroxy-2-methyl-4-(1H-1,2,4 -triazol-1-y)butyl)-1,3-dioxan-2-yl)-benzanilide; antifungal activity | SANKYO COMPANY, LIMITED (JP) | 2003-11-25 | — | — | US | disclosed |
| US-20030176480-A1 | For therapy and prophylaxis of fungal infections | SANKYO COMPANY, LIMITED (JP) | 2003-09-18 | — | — | US | disclosed |
| EP-1284267-A1 | TRIAZOLE COMPOUNDS HAVING AMIDE LINKAGE | Sankyo Company, Limited (JP) | 2003-02-19 | — | — | EP | disclosed |